What's in Bigespas LTD's pipeline?

Bigespas LTD has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Bigespas LTD's portfolio?

Top competitors by shared drug class: Capital Medical University, Peking Union Medical College Hospital, Rong Hu, MD, Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bigespas-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Bigespas LTD — Portfolio Competitive Intelligence Brief

Bigespas LTD pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
DMB-I (INN: Latrepirdine)	DMB-I (INN: Latrepirdine)	phase 3	Neuroprotective agent	NMDA receptor, mitochondrial membrane, monoamine oxidase	Neurology

Therapeutic area mix

Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Capital Medical University · 1 shared drug class
Peking Union Medical College Hospital · 1 shared drug class
Rong Hu, MD · 1 shared drug class
Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bigespas LTD:

Cite this brief

Drug Landscape (2026). Bigespas LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bigespas-ltd. Accessed 2026-05-15.